The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Findings from MATTERHORN support the use of immunotherapy in early-stage GC/GEJC
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the Phase III MATTERHORN study (NCT04592913), which supports the use of immunotherapy in early-stage resectable gastric/gastroesophageal junction cancer (GC/GEJC). Dr Janjigian highlights the benefits of introducing immunotherapy in early-stage GC/GEJC, noting that it has demonstrated improved survival and is well-tolerated. The regimen, which combines FLOT chemotherapy with durvalumab, has shown improved survival outcomes in global trials, making it a valuable option for patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
